Achievements

The Institute has made a huge contribution to the improvement of the territory of the Republic of Kazakhstan from highly dangerous infectious diseases of animals and birds using its own research and development results in the main area of its ​​scientific research:

– The Institute provides the agro-industrial complex of the Republic of Kazakhstan with 17 items of topical and urgently needed prophylactic and diagnostic products of domestic production, removing the country’s dependence on the purchase of imported products;

– The Institute has developed manufacturing techniques for 60 types of vaccines and diagnostic test systems;

– The release of 28 titles of vaccines is set up;

– Creation of a unique collection of microorganisms, where 1600 samples of 604 strains and isolates of pathogens of 61 infectious diseases of agricultural, wild animals, birds and humans are concentrated. Of the above number of virus strains, 13 nosomens are pathogens of especially dangerous diseases of animals and birds.

– Creation of a collection of grain crops and screening of samples resistant to rust and septorial diseases;

– For the first time in Kazakhstan, the Institute joined the World Federation of Culture Collections (WFCC);

– Creation of Institute’s own introduction and quarantine garden under the program “The Genefond of the Republic of Kazakhstan” to study foreign varieties of grain crops obtained through CIMMYT and the Ministry of Agriculture of the Republic of Kazakhstan;

– For the first time in the Republic of Kazakhstan, the genome structure of 29 strains and isolates of viruses has been deciphered, 16 test-systems have been developed for PCR-diagnostics of pathogens of especially dangerous infectious diseases;

– Development of technologies for the cultivation and maintenance of beta cells, hepatocytes and cardiomyocytes used in practical medicine for the treatment of patients with the method of transplantation;

– Formation of foundations of the National Gene Bank of especially dangerous infectious diseases;

– Establishment of the level of biological safety BSL-2 and BSL-3 in scientific laboratories, where studies are conducted with pathogens of especially dangerous infectious diseases of the group “A according to the OIE classification”;

– Creation of an information and communication environment that provides RIBSP access to world information resources;

– Development of a veterinary inactivated emulsified vaccine against highly pathogenic avian influenza Kazakhstan-15. The production and sale of this vaccine ensured stability in the epizootic and epidemiological situation of avian influenza in the Republic of Kazakhstan;

– Development of a technology for biochip diagnosis of influenza A virus subtypes and protein biochip for the diagnosis of brucellosis;

– Development of the HAIR, ELISA and RT-PCR test systems for identification and typing of subtypes of A type of BF virus, primers and DNA probes for the diagnosis and typing of the influenza virus;

– Development of a live vaccine against equine influenza based on a recombinant cold-adapted strain;

– For the first time in Kazakhstan, development of manufacturing technology of vaccines Kazfluvac against influenza A/H5N1 and Refluvac against influenza A/H1N1 for healthcare, and performance of preclinical and clinical trials of vaccines. Registration of vaccines in the Ministry of Health of the Republic of Kazakhstan;

– Development of a technology for the manufacture of Kazfluvir 3-valent vaccine against seasonal influenza for health care;

– Development of TB/FLU-04L vaccine for the prevention and treatment of human tuberculosis;

– Carrying out of pre-clinical, I-phase and II-phase-clinical tests on studying the safety and immunogenicity on the basis of the National Center for Tuberculosis Problems of the Ministry of Health of the Republic of Kazakhstan, National Centre for Expertise of Drugs, Medical Products and Medical Equipment of the Ministry of Healthcare of the Republic of Kazakhstan, in two research centers of the Russian Federation and the United Kingdom;

– Production of recombinant strains of brucellosis vaccine and, on its basis, development of a vector vaccine expressing brucella proteins with a pronounced specific CD4 + Tx-1 cellular immune response in animals;

– For the first time in Kazakhstan, carrying out of preclinical and phase I (44 people), phase II (300 people) and phase III (2000 people) clinical trials on the basis of polyclinics number 5 and number 15 in Almaty of a trivalent split vaccine against seasonal flu. Vaccine on the parameters of safety and immunogenicity showed compliance with the requirements of the State Pharmacopoeia of the Republic of Kazakhstan and the European Pharmacopoeia;

– Manufacture of an experimental microchip series for the express diagnosis of avian viral diseases;

– Production of diagnostic serum for influenza A virus;

– Design and production of recombinant sheep pox viruses;

– Identification of donors of wheat resistance to yellow rust based on DNA markers;

– Devepolment of a technology of manufacture of smallpox vaccine for camels;

– Devepolment of a manufacture technology of a vaccine against horse rhinopneumonia;

– Devepolment of a vector vaccine against small ruminant brucellosis;

– Devepolment of a technology of manufacturing a bivalent vaccine against porcine reproductive and respiratory syndrome of European and North American genotypes;

– Improvement of technology for obtaining diagnostic sera to the influenza virus;

– Devepolment of a vaccine for the prevention of pasteurellosis based on live attenuated mutant P.multocida strains;

– Creation of a universal vector based on capripoxvirus for the development of vaccines against infectious diseases.

– Development of manufacturing technology of cattle nodular dermatitis vaccine from the strain “Neethling-RIBSP”;

– Development of a disinfectant “Полифаг (Polyphage)” for the rehabilitation of medical facilities, food production and veterinary surveillance facilities.